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1

Abstract

2

Purpose: Left ventricular assist device (LVAD) support is associated with peripheral vascular

3

abnormalities beyond those associated with heart failure (HF). These abnormalities are associated

4

with persistent functional impairments that adversely impact quality of life (QoL). Methods for

5

measuring peripheral vascular function in this population are needed. Methods: This pilot study

6

investigated the use of contrast-enhanced ultrasound (CEUS) using standardized protocols to

7

estimate changes in peripheral (quadriceps) muscle perfusion among HF patients (INTERMACS

8

profile 3) undergoing LVAD implantation (n=7). Patients were then stratified by those who did

9

(“responders”, n=4) and did not (“non-responders”, n=3) report QoL improvement with LVAD

10

support. Results: Serial measurements obtained pre-operatively and 3 months following LVAD

11

implantation showed no significant change (p>0.23) in muscle perfusion by all CEUS-based

12

measures at rest or with exercise stimulus for the overall population. Responders exhibited

13

improved muscle perfusion at rest (p=0.043) and decreased time to peak contrast enhancement

14

(p=0.010) at 3 months compared to baseline, suggesting improved delivery of blood to the

15

extremities post-LVAD. Non-responders exhibited unchanged resting muscle perfusion (p>0.99),

16

time to peak contrast enhancement (p=0.59), and response to exercise stimulus (p>0.99) following

17

LVAD therapy. Conclusion: Our findings suggest that CEUS evaluation is a promising non-

18

invasive, quantitative modality for real-time assessment of peripheral vasculature and muscle

19

perfusion as an indication of treatment response in LVAD recipients, and that this modality may

20

capture perfusion measures important to QoL following LVAD implantation.

21
22
23

24

Introduction

25

Peripheral abnormalities, including those related to vascular function and skeletal muscle,

26

contribute to functional impairment and poor quality of life (QoL) in advance heart failure (HF)

27

patients, and have been implicated in frailty [1-3]. Left ventricular assist devices (LVADs), while

28

effective at correcting central hemodynamic derangements associated with advanced left HF, may

29

not correct these peripheral abnormalities. In fact, recent studies suggest continuous flow LVADs

30

are associated with additional peripheral vascular dysfunction, and such dysfunction may

31

contribute to persistent functional impairment and frailty, as well as GI bleeding [4-9].

32

While many frail LVAD recipients experience improvement in QoL with LVAD support,

33

up to half remain frail following LVAD implantation and report persistent poor QoL despite

34

LVAD support [4, 10-13]. These poorly-responding patients have similar pre-operative profiles as

35

those in whom frailty and QoL improve, and the mechanisms related to this variable response to

36

LVAD support are not known. We hypothesized that peripheral vascular abnormalities adversely

37

impact muscle perfusion, contributing to persistent frailty, functional impairment, and poor QoL

38

experienced by some HF patients following LVAD implantation.

39

In an effort to develop methods to study this further, this pilot study sought to investigate

40

the novel application of contrast-enhanced ultrasound (CEUS) to quantify skeletal muscle

41

perfusion in frail HF patients pre- and post-LVAD implantation. CEUS is a safe, non-invasive

42

technique that utilizes ultrasound contrast agents to provide image enhancement [14-16]. These

43

contrast agents are shell-stabilized, gas-filled, non-toxic microbubbles that, when injected

44

intravenously, act as harmonic oscillators within the ultrasound beam to increase the impedance

45

mismatch and enhance the resulting ultrasound image [14, 16]. CEUS is particularly useful in

46

imaging perfusion, improving differentiation between normal and abnormal flow conditions and

47

tissue delineation [16, 17]. While CEUS has been shown to provide valuable information regarding

48

limb perfusion in patients with peripheral artery disease [18, 19], this technology has not yet been

49

applied to muscle perfusion in the LVAD population.

50
51

Methods

52

Enrollment and Clinical Evaluation

53

Advanced HF patients approved for HeartMate II continuous flow LVAD (Thoratec,

54

Pleasanton, CA) implantation at Thomas Jefferson University Hospital (from April 2015 through

55

May 2017) were considered for enrollment in this IRB-approved study, provided that they were

56

ambulatory and not dependent on temporary mechanical circulatory support (INTERMACS

57

profile 3 or higher) at the time of pre-operative baseline testing. Nine patients agreed to participate

58

and provided signed informed consent, and seven of these patients completed follow up

59

assessments and are included in the present analysis (study n = 7).

60

CEUS exams (detailed below) and other clinical assessments were performed according to

61

standardized protocols by trained study personnel prior to LVAD implantation (baseline) and 3

62

months post-implantation. The clinical assessments included clinical frailty evaluation [20], knee

63

extensor strength, and QoL based on the Kansas City Cardiomyopathy Questionnaire (KCCQ).

64
65

Ultrasound Evaluation

66

CEUS exams were conducted on a standardized portion of the quadriceps muscle,

67

measured as half the distance between the patient’s femoral head and patella. The scan was first

68

performed in a resting state. A second exam was then performed in a fatigue state after an exercise

69

stimulus consisting of knee extension while an examiner provided resistance of approximately

70

50% of the patient’s maximum knee extensor strength with a handheld MicroFET 2 dynamometer

71

(Hoggan Scientific, Salt Lake City, UT) until exhaustion (i.e., until the participant was no longer

72

able to generate at least 50% of maximum knee extensor force).

73

CEUS scanning was performed using a Siemens S3000 Helx Evolution scanner (Siemens

74

Healthineers, Mountain View, CA) equipped with a C6 probe. For each of the CEUS exams, a

75

bolus injection of 0.3 mL of the UCA Definity (Lantheus Medical Imaging, N. Billerica, MA) was

76

administered intravenously. Definity is approved by the FDA for cardiac imaging, and this study

77

represents an off-label use for estimation of skeletal muscle perfusion. Definity has been shown to

78

effectively measure muscle perfusion in various applications [19, 21, 22]. CEUS imaging of

79

muscle perfusion can be augmented in patients with reduced blood flow, such as patients with

80

peripheral artery disease, by utilizing repetitive UCA destruction-replenishment sequences to

81

analyze muscle reperfusion at the resonant frequency of the microbubbles [19]. Therefore, during

82

each CEUS exam, three destruction-reperfusion sequences were acquired to quantitatively

83

evaluate muscle perfusion. These sequences consisted of destructive US pulses at a mechanical

84

index (MI) of 1.06, which was generated to rupture the UCA within the area of the muscle being

85

imaged, followed by nonlinear imaging at a lower intensity (MI of 0.04) to allow monitoring of

86

the UCA re-perfusion into the muscle.

87

Time-intensity curves and parametric maps were generated offline using Matlab

88

(MathWorks, Natick, MA) to estimate perfusion over the quadriceps muscle by calculating the

89

slope of the curve from the time contrast was first visualized to the peak intensity [17, 23, 24].

90

These data were used to calculate estimated muscle perfusion, contrast arrival time, and time to

91

peak contrast enhancement, which is defined as the time from contrast infusion to the point at

92

which maximum pixel intensity is reached. Muscle area was measured using the calipers feature

93

on the scanner on grayscale images acquired during each scanning session.

94
95

Statistical Analysis

96

Muscle perfusion analyses comparing baseline to 3-months post-LVAD were performed

97

for the population as a whole and stratified by change in KCCQ. An increase of 5 or more points

98

in the KCCQ is considered clinically meaningful [25, 26]. Patients reporting an increase 5 points

99

in the KCCQ at the 3 month examination were classified as “responders” to LVAD therapy, and

100

those who did not report improved QoL were classified as “non-responders”.

101

Statistical analysis was performed with GraphPad Prism 8 (GraphPad Software, La Jolla,

102

CA), using 2-way ANOVA and paired t-tests to compare the data within and between response

103

groups and observational time points with a 95% confidence interval. Vital statistics were

104

compared using paired Student’s t-tests. Results were collected in triplicate then averaged, and

105

error is reported as standard deviation (SD).

106
107

Results

108

Cohort-Based Evaluation

109

Baseline patient demographics and characteristics are reported in Table 1. Administration

110

of Definity contrast agent and subsequent CEUS examination were well-tolerated in all patients,

111

with no adverse effects, and provided substantial muscle enhancement imaging (Figures 1 and 2).

112

When evaluating the cohort as a whole, we found that muscle strength significantly

113

improved from baseline to 3 months post-LVAD (182.8 ± 67.3 dyn vs. 230.1 ± 62.3 dyn, p <

114

0.0001). However, there were no changes in any of the other clinical or physical function

115

parameters (p > 0.67).

116

Patients demonstrated response to exercise demand at baseline, exhibiting reduced time to

117

contrast arrival following exercise (-12.3 ± 7.7 seconds, p = 0.018) as well as reduced time to peak

118

contrast following exercise (-20.9 ± 38.4 seconds, p = 0.036). Patients retained response to exercise

119

demand at 3 months post-LVAD, with similar average decrease in contrast arrival time following

120

exercise (-14.9 ± 12.0 seconds, p = 0.003). However, there were no significant differences in any

121

of the CEUS parameters from baseline to 3 months post-LVAD (p > 0.09, Table 1).

122
123

Cohort Stratified by Change in QoL

124

When stratified based on QoL improvement, four patients were classified as responders

125

(17.25 ± 11.87 point increase in KCCQ score) and three were classified as non-responders (6.00 ±

126

8.19 point decrease in KCCQ score). Clinical evaluation outcomes and vitals for each subgroup

127

are shown in Table 1. Responders were more likely to have ischemic heart failure etiology (p <

128

0.0001) and higher body mass index (BMI) (p = 0.021) than those classified as non-responders.

129

Other baseline clinical characteristics were similar between responders and non-responders (p >

130

0.06).

131

At the 3-month evaluation, responders and non-responders showed no difference in LVAD

132

pump parameters (p > 0.14, Table S1), body weight and BMI (p > 0.12; Table S1). However,

133

responders exhibited a significantly lower Doppler blood pressure (79.5 ± 3.4 mmHg) compared

134

to non-responders (105.0 ± 5.0, p = 0.0002) despite similar blood pressure at baseline. Responders

135

also had a lower pulsatility index (5.9 ± 1.2) compared to non-responders (7.9 ± 0.6, p = 0.049).

136

Both groups exhibited similar (p = 0.70) improvements in muscle strength from baseline to 3

137

months post-LVAD (responders increased 46.0 ± 49.9 dyn, p = 0.009; non-responders increased

138

37.9 ± 40.8 dyn, p = 0.024). Non-responders exhibited slightly decreased quadriceps muscle

139

diameter at 3 months (-0.6 ± 0.5 cm, p = 0.004 compared to baseline), but no change in overall

140

muscle area (-0.5 ± 1.4 cm2, p = 0.39). Responders exhibited no change in either quadriceps muscle

141

diameter (+0.3 ± 1.5 cm, p = 0.58) or muscle area (+0.5 ± 3.0 cm2, p = 0.62) following LVAD

142

implantation. Muscle area was similar between responders and non-responders (Table S1, p >

143

0.28).

144

Summarized results from CEUS examinations are shown in Table 2. Baseline images from

145

a patient classified as a responder are shown in Figure 1, while images from this same patient at

146

3-months post-LVAD are shown in Figure 2. There is a noticeable difference in muscle perfusion

147

between the resting state and the fatigue state as seen by the difference in peak contrast

148

enhancement (compare Figs. 1B and 1D), indicating some baseline capacity to meet exercise-

149

induced demand in these peripheral muscles. Responders showed clear contrast enhancement

150

during the resting state 3 month post-LVAD examination (Fig. 2B), suggesting improved

151

peripheral blood flow in this population.

152

Quantitatively, responders exhibited significantly increased resting quadriceps muscle

153

perfusion from baseline to 3 months post-LVAD (12.5 ± 3.6 mL/s*mg vs. 41.7 ± 31.6 mL/s*mg,

154

p = 0.004), but not fatigue post-exercise (p = 0.70). Non-responders showed no significant

155

difference in quadriceps muscle perfusion from baseline to 3 months post-LVAD at rest or fatigue

156

(p > 0.54, Table 2).

157

Compared to baseline, time to peak contrast enhancement at 3 months post-LVAD was

158

significantly faster in responders at rest (85.1 ± 42.9 s vs. 51.2 ± 17.9 s, p = 0.010). However,

159

similar improvement was not observed in fatigue (p > 0.99). Among non-responders, the change

160

in time to peak contrast between baseline and 3 months post-LVAD was numerically longer at rest

161

(+12.9 ± 22.4 s) and fatigue (+8.0 ± 23.1 s), but neither of these differences was significant (p >

162

0.59).

163

At baseline, responders showed significant reduction in the time needed for contrast to

164

appear in the fatigued quadriceps muscle compared to resting (24.8 ± 8.3 s vs. 42.5 ± 5.1 s, p =

165

0.005). Similarly at 3 months post-LVAD, fatigue state contrast arrival time was significantly less

166

than at rest for responders (24.0 ± 1.8 s vs. 37.5 ± 6.5 s, p = 0.029). Non-responders showed no

167

significant differences in contrast arrival time between resting and fatigue state at baseline (p >

168

0.99) nor at 3 months post-LVAD (p = 0.20; Table 2). There were no significant differences in

169

resting or fatigue contrast arrival time between baseline and 3 months post-LVAD for either

170

response group (p > 0.82).

171
172

Discussion

173

To our knowledge, this is the first study to investigate the use of CEUS to assess skeletal

174

muscle perfusion in advanced HF patients receiving LVAD support. We found CEUS to be

175

feasible and well tolerated at rest and following exercise stimulus even in this advanced HF

176

population. Interestingly, there was no improvement in muscle perfusion for the overall cohort

177

following LVAD implantation. However, in the subgroup reporting improved QoL (“responders”),

178

there were consistent markers of improved delivery of blood to the periphery post-LVAD,

179

including improved resting muscle perfusion and decreased time to peak contrast enhancement

180

compared to baseline. No such improvements were present in LVAD recipients with no

181

improvement in QoL at 3 months (“non-responders”). We also identified baseline differences in

182

CEUS measures following exercise stimulus in responders vs. non-responders. In combination,

183

these pilot findings support CEUS assessment of muscle perfusion as feasible and clinically

184

meaningful in LVAD recipients.

185

The lack of overall improvement in skeletal muscle perfusion is surprising given the

186

increase in cardiac output provided by LVAD support. However, the validity of this finding is

187

supported by prior studies finding persistent and worsening peripheral vascular dysfunction with

188

continuous flow LVADs, possibly related to further compromised vasodilation from the lack of

189

pulsatility [4-6]. Some abnormalities have the potential to compromise muscle performance,

190

manifesting as persistent physical frailty and functional impairment [4, 11], with peak oxygen

191

consumption (VO2) often remaining ≤ 50% of predicted despite LVAD support [4, 10, 27].

192

There are several potential clinically impactful applications of CEUS supported by these

193

promising pilot findings. A recent study by Teigen et al. with computed tomography (CT) found

194

pectoralis muscle size and attenuation could predict clinical outcomes after LVAD implantation,

195

supporting the potential value of including skeletal muscle assessment when considering a patient

196

for LVAD implantation [3]. CEUS evaluation of skeletal muscle perfusion provides real-time

197

assessment of peripheral vascular performance not captured by other measures and with the

198

potential to enhance prognostic models [28].

199

Improvement in HF-related QoL, such as those measured by the KCCQ, is expected

200

following LVAD implantation. However, the response to LVAD support can be variable,

201

especially in older, frail recipients, in whom up to 50% remain frail and without significant

202

improvement in QoL following LVAD implantation [13, 29]. To date, there is no reliable method

203

to predict this lack of response to LVAD therapy prior to implantation [13, 28, 30-33]. Baseline

204

differences in CEUS measures of response to exercise stimulus in the “responder” vs. “non-

205

responders” warrant further investigation as potential predictors of subsequent response to LVAD

206

support [28].

207

Recent studies support the importance of peripheral vascular function and skeletal muscle

208

performance to health status in patents post-LVAD [34, 35]. Muscle strength and peak oxygen

209

uptake are independently associated with KCCQ outcomes, and knee extensor strength specifically

210

appears important to the health status of patients post-LVAD implantation [29, 34, 35]. Our

211

findings support peripheral vascular performance and related muscle perfusion as plausible

212

mechanisms for persistent frailty, functional impairments and poor QOL despite LVAD support.

213

If validated in a larger cohort, CEUS assessments could also potentially be used to assess response

214

to interventions targeting peripheral vasculature and skeletal muscle performance, such as exercise

215

interventions, medical therapies or optimization of LVAD settings [36-38].

216

This study has several limitations, including the small sample size, with only seven LVAD

217

recipients completing the 3-month follow-up assessments. In addition, all patients were treated

218

with the HeartMate II LVAD; patients receiving the newer HeartMate 3 were not included as this

219

was still an investigational device at the time of the study. Patients were only followed for 3 months

220

following LVAD implantation, at which point many LVAD recipients may still experience active

221

recovery from operative stress and long-standing clinical heart failure [13, 39]. Observations from

222

this study, while encouraging regarding the value of CEUS to assess muscle perfusion, require

223

confirmation in a larger sample size, over a longer duration (e.g. 6 months to a year) and in patients

224

with newly commercially available LVADs, such as the HeartMate 3.

225

Finally, we limited our pilot study to only the UCA Definity, although in vitro and animal

226

in vivo studies show that other UCAs are also effective in intermittent destruction-replenishment

227

CEUS perfusion imaging [19, 40]. Calculation of muscle perfusion rates is a useful tool for

228

estimating blood velocity, especially when assessing peripheral vascular behavior and adaptive

229

response to exercise demand [17, 18, 41]. We also found that skeletal muscle perfusion in these

230

patients increased with successive CEUS destruction-reperfusion pulses together with infusion of

231

UCAs, in agreement with other studies regarding patients with peripheral artery disease [18, 19].

232

Consequently, the use of CEUS may influence subsequent perfusion measures. However, the

233

CEUS protocol was applied consistently to all study participants at each assessment and this

234

phenomenon is unlikely to account for the study observations.

235
236

Conclusion

237

In this pilot study, we found that CEUS estimation of peripheral muscle perfusion was

238

feasible and well tolerated in advanced HF patients receiving LVAD support. Furthermore, we

239

found that preoperative changes in CEUS measures in response to exercise stimulus and

240

improvements in resting muscle perfusion following LVAD implantation were limited to those

241

patients reporting improved QoL. Although based on a limited sample size, these findings are

242

supported by prior studies reporting peripheral vascular dysfunction and persistent frailty

243

associated with poor QoL in up to 50% of frail LVAD recipients. Based on our findings, we

244

suggest that CEUS evaluation is a promising non-invasive, well-tolerated, quantitative modality

245

for assessment of peripheral vasculature and skeletal muscle perfusion that warrants further study

246

as a potential marker of prognosis and an indication of treatment response in LVAD recipients.

247
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258

Tables

259

Table 1: Pre-LVAD demographics of patient population (n=7), separated into responders (n=4)

260

and non-responders (n=3). Data is reported as mean ± standard deviation.

261
262
263
264
265
266
267
268

Whole Cohort
(n=7)

Responders
(n=4)

Non-Responders
(n=3)

Pre-Implant Data
Age, (years)

60.9 ± 5.2

60.8 ± 6.4

61.0 ± 4.6

Sex
Male, (%)

87.5

75.0

100.0

Race
Non-Hispanic White, (%)
Non-Hispanic Black, (%)

57.1
42.9

75.0
25.0

33.3
66.7

Heart Failure Etiology
Ischemic, (%)
Non-ischemic, (%)
Ejection Fraction, (%)

42.9
57.1
15.0 ± 5.8

75.0
25.0
15.0 ± 7.1

0.0
100.0
15.0 ± 5.0

Baseline Vitals
BMI, (kg/m2)
Systolic Blood Pressure, (mmHg)
Diastolic Blood Pressure, (mmHg)
Muscle Strength, (dyn)
Muscle Diameter, (cm)
Muscle Area, (cm2)

27.9 ± 5.5
105.4 ± 7.6
73.9 ± 6.0
182.8 ± 67.3
6.3 ± 0.8
9.0 ± 1.1

31.3 ± 4.5
108.0 ± 9.0
76.3 ± 6.7
220.5 ± 53.7
5.9 ± 0.8
8.5 ± 0.6

23.4 ± 2.6
102.0 ± 4.6
70.7 ± 3.8
168.8 ± 48.4
6.8 ± 0.3
9.7 ± 1.3

Characteristic Data
INTERMACS Profile, (1-7)
Fried Frailty Score, (1-5)
KCCQ Score, (0-100)

3±0
3±1
70 ± 16

3±0
3±1
66 ± 19

3±0
4±1
77 ± 10

269

Table 2: CEUS results for whole cohort (n=7), broken down into responders (n=4) and non-

270

responders (n=3). Data is reported as mean ± standard deviation, *p < 0.05, **p < 0.01.
Baseline

3 Months
Post Implant

Degree of Change
Post-LVAD

Resting
Fatigue
31.6 ± 105.8
37.9 ± 33.2
+ 6.3 ± 44.8

Resting
Fatigue
33.7 ± 26.0
34.0 ± 27.6
+ 0.3 ± 18.7

Resting
+2.2 ± 47.4

Fatigue
-3.9 ± 24.7

Contrast Arrival
Time, (s)

38.6 ± 6.7
26.3 ± 7.3
- 12.3 ± 7.7*

36.4 ± 8.4
21.6 ± 6.7
- 14.9 ± 12.0**

- 2.1 ± 10.7

- 4.7 ± 8.9

Time to Peak
Contrast, (s)

65.7 ± 39.5
44.8 ± 13.2
- 20.9 ± 38.4*

51.8 ± 21.2
44.5 ± 19.6
- 7.4 ± 5.5

- 13.9 ± 51.5

- 0.2 ± 22.3

Muscle Perfusion,
(mL/s*mg)

Resting
Fatigue
12.5 ± 3.6 36.8 ± 44.3
+ 24.3 ± 44.9

Resting
Fatigue
41.7 ± 31.6 43.1 ± 33.1
+ 1.5 ± 25.3

Resting
+ 29.2 ± 36.4**

Fatigue
+ 6.4 ± 28.7

Contrast Arrival
Time, (s)

42.5 ± 5.1 24.8 ± 8.3
- 17.8 ± 4.8**

37.5 ± 6.5
24.0 ± 1.8
- 13.5 ± 5.7*

- 5.0 ± 10.0

- 0.8 ± 8.6

85.1 ± 42.9 49.9 ± 13.5
- 35.3 ± 47.8**

51.2 ± 17.8
43.5 ± 17.9
- 8.0 ± 7.0

- 34.0 ± 58.6**

- 6.4 ± 20.4

Resting
Fatigue
57.0 ± 163.4
39.3 ± 7.5
- 17.7 ± 38.7

Resting
Fatigue
23.2 ± 9.6
21.8 ± 10.4
- 1.3 ± 9.3

Resting
- 33.8 ± 36.8

Fatigue
- 17.5 ± 10.4

Contrast Arrival
Time, (s)

33.3 ± 4.9
28.3 ± 6.8
- 5.0 ± 2.0

35.0 ± 12.0
18.3 ± 10.0
- 16.7 ± 19.4

+ 1.7 ± 12.5

- 10.0 ± 7.2

Time to Peak
Contrast, (s)

39.8 ± 7.1
38.0 ± 9.7
- 1.8 ± 5.7

52.6 ± 26.1
46.0 ± 22.7
- 6.7 ± 4.1

+ 12.9 ± 22.4

+ 8.0 ± 23.1

Whole Cohort
(n=7)
Muscle Perfusion,
(mL/s*mg)

Responders
(n=4)

Time to Peak
Contrast, (s)

Non-Responders
(n=3)
Muscle Perfusion,
(mL/s*mg)

271
272
273
274

275
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409

Figure Legends

410
411

Figure 1: CEUS images of quadriceps muscle at baseline from a patient classified as a

412

responder. A) Pre-infusion image taken in the resting state, muscle and bone are delineated on

413

the image. B) Image taken during peak contrast enhancement in the resting state, showing little

414

change in contrast enhancement, and therefore little muscle perfusion. C) Pre-infusion image

415

taken in the fatigue state. D) Image taken during peak contrast enhancement in the fatigue state,

416

showing a more noticeable increase in contrast and therefore increased muscle perfusion.

417
418
419

Figure 2: CEUS images of quadriceps muscle at 3 months post-LVAD implantation for the same

420

patient as in Figure 1, who was classified as a responder. A) Pre-infusion image taken in the

421

resting state, muscle and bone are delineated on the image. B) Image taken during peak contrast

422

enhancement in the resting state, showing increased contrast enhancement and therefore

423

increased muscle perfusion (compared to baseline, 1B). C) Pre-infusion image taken in the

424

fatigue state. D) Image taken during peak contrast enhancement in the fatigue state, showing

425

greater contrast enhancement and therefore greater muscle perfusion.

426

